This website uses cookies to improve the site and user experience. By continuing to browse this site,
you agree to accept our use of cookies. For more information, please review our Cookies Policy
SGO 2022
Presentations
Tisotumab Vedotin | Cervical Cancer
Tisotumab Vedotin (TV) + Carboplatin (Carbo) in First-line (1L) or + Pembrolizumab (Pembro) in Previously Treated (2L/3L) Recurrent or Metastatic Cervical Cancer (r/mCC): Interim Results of ENGOT-Cx8/GOG-3024/innovaTV 205 Study
Tisotumab Vedotin | Cervical Cancer
Real-world treatment pattern and drop-off among recurrent or metastatic cervical cancer patients: a US community oncology-based analysis
Tucatinib | Solid Tumors
SGNTUC-019 Phase 2 basket study of tucatinib and trastuzumab in solid tumors with human epidermal growth factor receptor 2 alterations: uterine and cervical cancer cohorts